- Home
- NTWK vs IGC Comparison
NTWK vs IGC Comparison
Compare NTWK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTWK
- IGC
- Stock Information
- Founded
- NTWK 1997
- IGC 2005
- Country
- NTWK United States
- IGC United States
- Employees
- NTWK N/A
- IGC N/A
- Industry
- NTWK Computer Software: Prepackaged Software
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NTWK Technology
- IGC Health Care
- Exchange
- NTWK Nasdaq
- IGC Nasdaq
- Market Cap
- NTWK 31.1M
- IGC 29.4M
- IPO Year
- NTWK 1998
- IGC N/A
- Fundamental
- Price
- NTWK $2.68
- IGC $0.36
- Analyst Decision
- NTWK
- IGC Strong Buy
- Analyst Count
- NTWK 0
- IGC 2
- Target Price
- NTWK N/A
- IGC $3.75
- AVG Volume (30 Days)
- NTWK 28.7K
- IGC 393.7K
- Earning Date
- NTWK 02-11-2025
- IGC 02-12-2025
- Dividend Yield
- NTWK N/A
- IGC N/A
- EPS Growth
- NTWK N/A
- IGC N/A
- EPS
- NTWK 0.06
- IGC N/A
- Revenue
- NTWK $61,749,408.00
- IGC $1,183,000.00
- Revenue This Year
- NTWK N/A
- IGC N/A
- Revenue Next Year
- NTWK N/A
- IGC $13.38
- P/E Ratio
- NTWK $41.84
- IGC N/A
- Revenue Growth
- NTWK 14.50
- IGC N/A
- 52 Week Low
- NTWK $1.99
- IGC $0.27
- 52 Week High
- NTWK $3.34
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- NTWK 51.07
- IGC 51.08
- Support Level
- NTWK $2.62
- IGC $0.31
- Resistance Level
- NTWK $2.73
- IGC $0.36
- Average True Range (ATR)
- NTWK 0.10
- IGC 0.02
- MACD
- NTWK 0.01
- IGC 0.00
- Stochastic Oscillator
- NTWK 50.00
- IGC 75.00
About NTWK NetSol Technologies Inc. Common Stock
NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions. Its products and services include NFS Ascent, NFS Digital, Leasepak Cloud, Business consultancy, and information security services among others. The firm has North America, Europe, and Asia-Pacific segments, of which the majority of the revenue is derived from Asia-Pacific. It derives revenue from licensing, customization, enhancements, and maintenance of its financial applications. The company promotes and sells its products under the Netsol financial suite.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.